| 17th Jan 2022 9:00 am |
RNS |
Holding(s) in Company |
| 12th Jan 2022 11:00 am |
RNS |
Breakthrough Therapy Designation for HMPL-523 |
| 10th Jan 2022 7:00 am |
RNS |
HUTCHMED Initiates Phase I Study of HMPL-760 |
| 31st Dec 2021 7:00 am |
RNS |
Blocklisting Six Monthly Return |
| 31st Dec 2021 7:00 am |
RNS |
Total Voting Rights |
| 20th Dec 2021 7:00 am |
RNS |
HUTCHMED Included in FTSE Russell Indexes |
| 15th Dec 2021 9:45 am |
RNS |
Grant of Share Options and Awards under LTIP |
| 14th Dec 2021 7:00 am |
RNS |
HMPL-523 Clinical Data Presented at ASH |
| 10th Dec 2021 10:00 am |
RNS |
HUTCHMED Presents Data at ESMO Immuno-Oncology ‘21 |
| 6th Dec 2021 7:00 am |
RNS |
HUTCHMED Completes Planned Enrollment of FRESCO-2 |
| 3rd Dec 2021 7:00 am |
RNS |
Updated NRDL to include ELUNATE and SULANDA |
| 30th Nov 2021 8:30 am |
RNS |
Total Voting Rights |
| 24th Nov 2021 7:00 am |
RNS |
HUTCHMED and AZ Initiate SACHI Phase 3 Trial |
| 8th Nov 2021 7:00 am |
RNS |
HUTCHMED to Present Clinical Data at ASH |
| 1st Nov 2021 7:00 am |
RNS |
HUTCHMED and AZ Initiate SAMETA Global P3 Trial |
| 29th Oct 2021 9:30 am |
RNS |
Total Voting Rights |
| 28th Oct 2021 7:00 am |
RNS |
HUTCHMED Initiates Phase III Trial of HMPL-523 |
| 20th Oct 2021 9:30 am |
RNS |
Grant of Awards under Long Term Incentive Plan |
| 30th Sep 2021 9:30 am |
RNS |
Total Voting Rights |
| 29th Sep 2021 7:00 am |
RNS |
Closure of Non-Core OTC Joint Venture Divestment |
| 29th Sep 2021 7:00 am |
RNS |
HUTCHMED Highlights Presentations at CSCO 2021 |
| 21st Sep 2021 7:00 am |
RNS |
HUTCHMED Initiates Phase III Trial SURTORI-01 |
| 20th Sep 2021 7:00 am |
RNS |
Japan Bridging Study For Surufatinib Initiated |
| 13th Sep 2021 7:00 am |
RNS |
Breakthrough Therapy Designation for Amdizalisib |
| 8th Sep 2021 11:30 am |
RNS |
HUTCHMED and AZ Initiate Phase III Trial in China |
| 7th Sep 2021 9:30 am |
RNS |
HUTCHMED to Present Clinical Data at ESMO |
| 2nd Sep 2021 12:45 pm |
RNS |
Grant of Share Options, and Awards under LTIP |
| 31st Aug 2021 9:30 am |
RNS |
Total Voting Rights |
| 26th Aug 2021 7:00 am |
RNS |
Phase Ib/II Trial of Fruquintinib & Tislelizumab |
| 23rd Aug 2021 7:00 am |
RNS |
HUTCHMED Selected for Certain Hang Seng Indexes |
| 17th Aug 2021 9:30 am |
RNS |
ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION |
| 9th Aug 2021 7:00 am |
RNS |
HUTCHMED & Epizyme Announce TAZVERIK Collaboration |
| 30th Jul 2021 9:30 am |
RNS |
Total Voting Rights |
| 28th Jul 2021 12:00 pm |
RNS |
Interim Results and Business Updates |
| 28th Jul 2021 7:00 am |
RNS |
Phase II Trial of ORPATHYS Initiated |
| 23rd Jul 2021 12:01 pm |
RNS |
Stabilizing Actions & End of Stabilization Period |
| 16th Jul 2021 10:50 am |
RNS |
Holding(s) in Company |
| 16th Jul 2021 7:00 am |
RNS |
Surufatinib MAA Submitted and Validated by the EMA |
| 14th Jul 2021 9:35 am |
RNS |
Holding(s) in Company |
| 13th Jul 2021 7:00 am |
RNS |
First Commercial Sale of ORPATHYS® in China |
